Disease · MONDO_0020546
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Palifermin vs Placebo: serious adverse events | 50 of 78 | 40 of 73 | 151 | NCT00189488 | Trial comparisons |
| Sirolimus vs Prednisone: deaths from any cause | 12 of 58 | 17 of 64 | 122 | NCT02806947 | Trial comparisons |
| Sirolimus vs Prednisone: serious adverse events | 8 of 58 | 3 of 64 | 122 | NCT02806947 | Trial comparisons |
| BEGEDINA® (Begelomab) vs Conventional Second-line Treatment: deaths from any cause | 13 of 18 | 8 of 18 | 36 | NCT02411084 | Trial comparisons |
| BEGEDINA® (Begelomab) vs Conventional Second-line Treatment: serious adverse events | 16 of 18 | 13 of 18 | 36 | NCT02411084 | Trial comparisons |
| Vedolizumab 300 mg vs Vedolizumab 600 mg: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) | 8 of 8 | 9 of 9 | 17 | NCT02993783 | Trial comparisons |
| Vedolizumab 300 mg vs Vedolizumab 600 mg: Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 32 | 6 of 8 | 9 of 9 | 17 | NCT02993783 | Trial comparisons |
| Vedolizumab 300 mg vs Vedolizumab 600 mg: Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 28 | 3 of 8 | 4 of 9 | 17 | NCT02993783 | Trial comparisons |
| Vedolizumab 300 mg vs Vedolizumab 600 mg: deaths from any cause | 4 of 8 | 9 of 9 | 17 | NCT02993783 | Trial comparisons |
| Vedolizumab 300 mg vs Vedolizumab 600 mg: serious adverse events | 6 of 8 | 9 of 9 | 17 | NCT02993783 | Trial comparisons |
| T-Guard vs Ruxolitinib: Complete Response (CR) | 2 of 7 | 0 of 5 | 12 | NCT04934670 | Trial comparisons |
| T-Guard vs Ruxolitinib: Duration of Complete Response (DoCR) | 2 of 7 | 0 of 5 | 12 | NCT04934670 | Trial comparisons |
| T-Guard vs Ruxolitinib: Overall Survival (OS) | 4 of 7 | 1 of 5 | 12 | NCT04934670 | Trial comparisons |
| T-Guard vs Ruxolitinib: deaths from any cause | 4 of 7 | 1 of 5 | 12 | NCT04934670 | Trial comparisons |
| T-Guard vs Ruxolitinib: serious adverse events | 5 of 7 | 2 of 5 | 12 | NCT04934670 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020546/comparisons